Rimonabant, antagonist at CB1, has long been used as an anti-obesity drug able to induce weight loss, improve blood lipid parameters and increase the adiponectin level in obese patients [67], but it had severe side effects including depression, anxiety, nausea and dizziness probably due to the blockade of central CB1. Here, ADIPOQ is linked to obesity disorder.